(Q37275477)

19 August 2017

1 reference

title

Bcl-2 inhibitors: small molecules with a big impact on cancer therapy (English)

1 reference

19 August 2017

M Vogler

1

1 reference

19 August 2017

D Dinsdale

series ordinal

2

1 reference

19 August 2017

M J S Dyer

series ordinal

3

1 reference

19 August 2017

G M Cohen

series ordinal

4

1 reference

19 August 2017

19 September 2008

1 reference

Cell Death & Differentiation

19 August 2017

1 reference

19 August 2017

16

1 reference

19 August 2017

360-367

1 reference

19 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1038/cdd.2008.137

19 August 2017

0 references

cites work

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Apoptotic death sensor: an organelle's alter ego?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Cell death: critical control points

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

The Bcl-2 apoptotic switch in cancer development and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

The Bcl2 family: regulators of the cellular life-or-death switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

The BCL-2 protein family: opposing activities that mediate cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

BH3-Only proteins-essential initiators of apoptotic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Targeting protein-protein interactions for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Identification of chelerythrine as an inhibitor of BclXL function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Small-molecule inhibitors of Bcl-2 family proteins as therapeutic agents in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

A novel Bcl-2 small molecule inhibitor 4-(3-methoxy-phenylsulfannyl)-7-nitro-benzofurazan-3-oxide (MNB)-induced apoptosis in leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Chelerythrine and sanguinarine dock at distinct sites on BclXL that are not the classic BH3 binding cleft

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Targeting multiple arms of the apoptotic regulatory machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Programmed anuclear cell death delimits platelet life span.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Bcl-xL induces Drp1-dependent synapse formation in cultured hippocampal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

inferred from DOI database lookup

7 January 2021

based on heuristic

Bcl-2 family proteins are essential for platelet survival.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

inferred from DOI database lookup

7 January 2021

based on heuristic

The pathways of cell death: oncosis, apoptosis, and necrosis

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2008.137

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CDD.2008.137

1 reference

19 August 2017

1 reference